In the Phase 2 clinical trial (NEJM, 2023), retatrutide was administered subcutaneously at doses ranging from approximately 0.5 mg to 12 mg per week, with dose escalation under close medical supervision
For a broader comparison that includes tirzepatide, liraglutide, and insurance strategies, see our GLP-1 cost comparison guide
It is a Schedule IV controlled substance class of drug in terms of how it will be regulated, similar to other injectable weight-loss medications
Classic examples include: Nitroglycerin, which undergoes such extensive first-pass metabolism that sublingual administration becomes essential
95% CI 0.79 1.16
Once you reach a stable dose and side effects diminish, timing becomes a lifestyle choice rather than a clinical one